查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847875

肺炎鏈球菌檢測市場：按檢測類型、技術、應用、最終用戶和分銷管道分類 - 全球預測（2025-2032 年）

Pneumococcal Testing Market by Type Of Test, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺炎球菌檢測市場規模將達到 36.7 億美元，複合年成長率為 9.25%。

主要市場統計數據
基準年 2024 18億美元
預計年份：2025年 19.7億美元
預測年份：2032年 36.7億美元
複合年成長率 (%) 9.25%

這份策略性入門指南重點闡述了近期診斷技術的進步、臨床需求和監測需求如何改變肺炎球菌檢測和實驗室工作的重點。

肺炎鏈球菌感染持續帶來複雜的臨床和公共衛生挑戰，檢測技術的進步在改善患者預後和指導預防策略方面發揮核心作用。如今，診斷工作需要在分子準確性、快速照護現場和以監測主導的公共衛生干預措施之間取得平衡。因此，實驗室主任、臨床微生物學家和公共衛生負責人必須在營運限制和監管要求的框架內權衡診斷的準確性、通量和及時性。

近年來，診斷創新已從純培養鑑定轉向更精細的分子和血清學方法，從而實現更早期、特異性的檢測。這一發展與疫苗接種計劃的擴展以及對血清型分佈和抗生素抗藥性監測需求的日益成長相吻合。同時，醫療衛生系統正在調整採購和檢測管道，以適應多重檢測平台和整合數據報告功能，從而更好地支援臨床決策和流行病學追蹤。

在此背景下，相關人員必須權衡近期臨床效用與對基礎設施、人才團隊建設和資訊系統的長期投資。引入新型檢測方法和分析技術需要謹慎的驗證和實施策略，以在確保診斷品質的同時，最大限度地應對實際應用中的各種限制。如今在檢測方法選擇、實驗室工作流程和監測方案設計方面所做的決定，將決定下一代肺炎鏈球菌控制措施及其降低發病率和死亡率的能力。

技術進步、數據系統整合和臨床管道的改變將從根本上改變肺炎球菌檢測和監測的方法。

由於技術的成熟、臨床管道的轉變以及公共衛生重點的不斷變化，肺炎球菌檢測領域正在發生顯著變化。分子檢測方法靈敏度更高，且能夠在一次檢測中檢測多個靶標，正推動著檢測方法從傳統的僅培養法轉變為分子檢測方法的轉變。同時，血清學方法也得到了改進，能夠快速檢測抗體和抗原，從而可以更迅速地評估免疫狀態和疫苗效力。

檢測也日益與數位健康和​​實驗室資訊系統融合，增強了臨床機構與公共衛生部門之間的數據流動。這種融合支持對血清流行率和抗藥性模式的即時監測，從而能夠更快地做出公共衛生應對。此外，越來越多的就地檢驗選擇正在擴大門診病人和社區的檢測管道，改變檢體收集管道和診斷管理模式。

另一項重大轉變是強調能夠同時識別和表徵病原體的多重檢測和基因組學方法。這些方法有助於進行準確的流行病學追蹤並為疫苗政策決策提供資訊，同時也對實驗室生物資訊學和數據管治提出了新的要求。因此，診斷試劑生產商、臨床實驗室和公共衛生機構之間的合作正在加速，戰略夥伴關係在部署可擴展且永續的檢測解決方案方面發揮著日益重要的作用。

評估2025年關稅如何改變了肺炎球菌診斷生態系統的籌資策略、供應鏈韌性和平台選擇

2025年關稅的實施對肺炎球菌檢測用品和設備的採購、生產和分銷動態產生了廣泛影響。進口關稅和貿易調整影響了試劑、設備和耗材的採購決策，促使許多相關人員重新評估其供應商組合和供應鏈韌性。因此，診斷試劑生產商和實驗室網路正在調整其生產和庫存策略，以維持檢測服務的連續性。

在營運方面，各實驗室面臨是否優先使用現有平台，或是投資於受關稅價格波動影響較小的替代技術的抉擇。採購團隊的因應措施包括：協商長期供應協議、拓展與當地經銷商的關係，以及在某些情況下加速對國內生產能力的投資。這種轉變也影響了前置作業時間和物流規劃，各公司更重視雙軌供應策略和緩衝庫存，以降低供應中斷的風險。

監管機構和負責人致力於在確保獲得必要診斷服務的同時，兼顧成本控制目標。支付方和醫院管理者加強了對檢測使用情況的審查，以維持預算穩定，這影響了高成本檢測平台的推廣應用。同時，關稅壓力推動了供應鏈區域化，並促進了優先考慮供應安全和符合當地市場要求的夥伴關係模式的建立。綜上所述，這些動態凸顯了策略採購、靈活選擇檢測平台以及積極主動的供應鏈管治對於在不斷變化的貿易環境下維持診斷能力的重要性。

深入的細分分析揭示了檢測方式、賦能技術、臨床應用、終端用戶環境和分銷模式將如何推動診斷技術的普及應用。

了解市場區隔對於制定產品開發、研發和實驗室應用策略至關重要。從檢測類型來看，市場涵蓋培養法、分子檢測和血清學工具。基於培養的檢測方法仍適用於抗菌藥物敏感性試驗和確證鑑定，其分為自動化培養系統（可提高通量）和傳統培養方法（在許多診斷流程中仍然必不可少）。分子檢測的特點是數位PCR、多重PCR和即時PCR的興起，這些技術能夠實現快速且靈敏的檢測，並可同時分析多個標靶。血清學方法包括酵素結合免疫吸附檢測法（ELISA）和快速免疫檢測測定，可用於免疫狀態​​評估和疫苗反應監測。 ELISA平台通常用於詳細的血清型和抗體譜分析，而快速免疫檢測則用於分散式檢測。

技術細分有助於更清楚地了解競爭格局和臨床應用現狀。 ELISA平台分為間接法和夾心法，分別適用於不同的抗原-抗體動態變化。免疫層析法包括斑點印跡法和側向流動法，適用於快速篩檢和照護現場。新一代定序平台，例如Illumina和Ion Torrent，可提供高解析度的血清型分佈和基因組監測功能，從而更深入地了解病原體的演化。 PCR檢測仍然是一項關鍵技術，其中數位PCR可提供絕對定量，即時PCR兼顧了速度和分析性能。

應用主導細分揭示了診斷效用在攜帶者篩檢、診斷、監測和疫苗評估中的差異。帶因者篩檢區分鼻咽拭子和口咽拭子採樣方法，而診斷應用涵蓋社區型肺炎、腦膜炎和中耳炎等臨床症候群。監測活動著重於抗生素抗藥性監測和血清型分佈，以指導公共衛生干預措施，而疫苗評估則著重於臨床前實驗室數據和上市後監測，以衡量疫苗的實際有效性。最終使用者細分則著重於檢測的運作環境，從社區健康中心和門診診所到大型和小型醫院、地方和州級公共衛生實驗室以及國家和地區級參考實驗室，每個機構都有不同的工作流程、法規和預算考量。最後，分銷管道多種多樣，包括線上直銷入口網站或專業銷售團隊、經銷商、區域或全國性經銷商，以及包括電子商務產品和製造商入口網站在內的線上平台，從而創造了多種市場管道和服務模式，供應商必須最佳化這些管道和服務模式才能接觸到各種各樣的買家。

一項比較區域研究，旨在探討政策架構、實驗室能力和供應鏈策略如何影響全球肺炎鏈球菌檢測市場。

區域動態對診斷部署、監管管道和投資重點有顯著影響。在美洲，臨床實驗室和公共衛生機構優先考慮快速、高通量檢測，以支援臨床管理和廣泛的監測需求。該地區的醫療衛生系統傾向於採用能夠與電子健康記錄和公共衛生報告基礎設施整合的多重檢測和分子檢測平台，而支付方系統則更注重檢測管道的成本效益和價值驅動。

歐洲、中東和非洲是一個異質性區域，其監管環境、報銷模式和公共衛生重點差異巨大。在一些地區，先進的參考實驗室和國家監測計畫正利用次世代定序和基因組流行病學技術繪製血清型轉變圖譜，而資源匱乏的地區則更依賴照護現場血清學和層析法檢測來擴大檢測範圍。跨境合作與能力建構仍是核心議題，相關人員日益重視資料標準的統一，以確保不同轄區之間監控結果的可比較性。

在亞太地區，診斷基礎設施的成長和對本地製造的投資顯而易見，各國政府和相關人員優先考慮試劑生產和儀器服務的本土化能力。該地區正迅速採用數位化工作流程和分散式檢查模式，並成為公私合營的活躍平台，旨在擴大監測和疫苗評估計畫的規模。各地區的供應鏈策略和監管互動都根據當地市場結構量身定做，這就要求供應商設計靈活的商業模式，既要考慮到這些區域差異，又要確保品質和合規性。

提供公司層面的實用訊息，包括平台策略、策略夥伴關係和營運支持，這些資訊將決定肺炎球菌診斷領域的成功。

這些企業級動態的核心在於平台多元化、策略夥伴關係以及商業模式與不斷變化的實驗室需求的契合。診斷試劑製造商正增加涵蓋中心實驗室設備、床邊分析儀和耗材生態系統等產品線的投資，以確保持續收入並深化客戶關係。同時，他們也更加關注能夠實現多重檢測、血清分型以及與數位彙報工具整合的檢測方法，以支援監測和臨床決策。

隨著企業尋求提供能夠減少實驗室實施摩擦的端到端解決方案，檢測開發人員、設備供應商和資訊系統提供者之間的夥伴關係日益普遍。同樣，受託製造廠商和特殊試劑供應商在確保供應連續性方面發揮著至關重要的作用，尤其是在地緣政治或貿易政策變化導致採購不確定性時。市場競爭者也增加對監管管道和臨床證據的投入，以支持更廣泛的適應症，例如門診應用和公共衛生監測。

實驗室網路和參考實驗室透過參與驗證研究、通訊協定協調和外部品質評估專案發揮影響力，進而影響新檢測方法的應用模式。那些能夠提供強而有力的售後支援、快速回應的技術服務和便利的培訓資源的公司，往往能在分散的市場環境中獲得更深層的滲透。總體而言，最成功的公司會將技術差異化與務實的商業化策略相結合，以滿足不同終端使用者的實際業務需求。

針對診斷和檢測產業領導者的具體策略行動，旨在增強互通性、供應鏈韌性、證據產生和客製化商業化方法。

產業領導者應優先採取一系列切實可行的措施，以鞏固市場地位並支持公共衛生目標。首先，投資於平台互通性和數據整合能力將有助於提高產品普及率，因為實驗室越來越需要儀器、實驗室資訊系統和公共衛生資料庫之間的無縫連接。透過消除整合障礙，企業可以加快客戶實現價值的速度，並加強長期合作關係。

其次，透過多元化採購、區域製造夥伴關係和可擴展的庫存策略來增強供應鏈韌性，可以降低貿易中斷和關稅波動帶來的風險。策略採購安排以及與客戶前置作業時間和緊急時應對計畫進行透明溝通，有助於增強信任和業務永續營運。第三，針對不同臨床適應症、檢體類型和人群產生檢驗產品性能的針對性證據，有助於獲得更廣泛的臨床認可和監管靈活性。強大的上市後監測和真實世界性能數據也有助於產品迭代改進。

第四，根據終端用戶需求客製化市場推廣策略——例如針對社區診所、大型醫院系統、公共衛生實驗室和參考實驗室提供差異化產品和服務——可以提高市場滲透率。這包括提供模組化培訓、遠端支援和靈活的銷售條款，以反映各個細分市場的採購偏好。最後，上市公司應積極與公共衛生相關人員和支付方溝通，使其診斷提案主張與政策重點和報銷框架保持一致。這些綜合措施有助於應對不確定性，同時持續創造臨床和公共衛生價值。

調查方法，結合相關人員訪談、文獻回顧和跨領域分析，旨在提供可操作的診斷和政策見解。

支持這些見解的研究採用了多模態方法，以確保研究的整體性和實用性。主要研究包括對實驗室主任、臨床微生物學家、採購人員和公共衛生官員進行結構化訪談和定性諮詢，以了解當地的營運觀點和決策標準。與這些相關人員的互動為平台選擇、驗證要求和供應鏈敏感性提供了詳細的背景資訊，有助於解讀診斷和監測領域的新興趨勢。

我們的二次研究綜合了公開的監管指南、技術白皮書以及關於肺炎球菌診斷、血清型流行病學和檢測方法的同行評審文獻。我們專注於同儕審查的檢驗研究和官方公共衛生通報，以確保我們的技術評估基於嚴謹的證據。在適當情況下，我們審查了公司揭露的資訊和產品技術規格，以比較不同平台的功能集和整合能力。

分析方法包括交叉細分映射，以識別臨床需求與技術能力的交集；以及情境分析，以探討供應鏈或專案變更可能導致的招募管道變化。品質保證措施包括利用多個獨立資訊來源檢驗定性調查結果，並由臨床專家進行迭代審查，以確保解讀結果反映實際情況。這種混合調查方法產生了可靠且可操作的見解，可為採購決策、平台投資和專案參與指南。

最後總結指出，技術創新、供應鏈穩健性和公共衛生策略合作之間的相互作用有助於減輕肺炎鏈球菌感染。

最後，肺炎球菌檢測領域正處於曲折點交匯融合。分子和定序技術正在釋放新的診斷和監測途徑，而血清學檢測和照護現場方法則持續擴大分散環境下的檢測覆蓋範圍。這些互補的方法為臨床醫生和公共衛生官員提供了更豐富的套件，但也要求我們更加重視互通性、檢驗和品質保證。

近期政策變化和貿易動態的累積效應，凸顯了製定具有韌性的籌資策略和靈活商業模式的必要性。同時，各地法規和檢測能力的差異，要求供應商提供靈活的部署方案，以適應當地的限制和優先事項。積極主動地整合資源、累積證據並確保供應的公共機構和實驗室網路，將更有利於滿足當前的臨床需求和實現長期的公共衛生目標。

為了成功應對這一局面，透明的數據共用和切實可行的實施管道需要LED、製造商、實驗室和公共衛生機構之間的密切合作。透過將技術創新與實際應用和相關人員的需求相結合，診斷產業可以為減輕肺炎鏈球菌感染負擔和加強未來的監測系統做出實際貢獻。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合多種分子檢測方法以快速鑑定肺炎球菌血清型和共存呼吸道病原體
  • 在服務不足和資源匱乏地區擴大即時聚合酵素鏈鎖反應檢測肺炎鏈球菌的規模
  • 利用新一代定序技術對肺炎鏈球菌菌株多樣性和抗生素抗藥性譜進行高解析度監測
  • 開發自動化樣本到結果平台，以加快醫院和臨床實驗室的工作流程
  • 推出雲端基礎的數據分析和數位報告工具，用於即時監測肺炎鏈球菌感染爆發情況

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 按檢測類型分類的肺炎鏈球菌檢測市場

  • 文化
    • 自動培養
    • 傳統文化
  • 分子
    • 數位PCR
    • 多重PCR
    • 即時PCR
  • 血清學
    • ELISA
    • 快速免疫檢測

9. 按技術分類的肺炎鏈球菌檢測市場

  • ELISA
    • 間接ELISA
    • 夾心ELISA
  • 層析法試驗
    • 點印法
    • 橫向流動化驗
  • 下一代定序
    • Illumina平台
    • 離子洪流
  • PCR檢測
    • 數位PCR
    • 多重PCR
    • 即時PCR

第10章 按應用分類的肺炎鏈球菌檢測市場

  • 攜帶者篩檢
    • 鼻咽篩檢
    • 口咽篩檢
  • 診斷
    • 社區型肺炎
    • 腦膜炎
    • 中耳炎
  • 監測
    • 抗生素抗藥性監測
    • 血清型分佈
  • 疫苗評估
    • 上市後監測
    • 臨床前試驗

第11章 依最終用戶分類的肺炎鏈球菌檢測市場

  • 診所
    • 社區健康中心
    • 門診部
  • 醫院
    • 大型醫院
    • 小型醫院
  • 公共衛生實驗室
    • 當地公共衛生實驗室
    • 州公共衛生實驗室
  • 參考實驗室
    • 國家參考實驗室
    • 區域參考實驗室

第12章 肺炎鏈球菌檢測市場（依通路分類）

  • 直銷
    • 線上
    • 專業銷售團隊
  • 經銷商
    • 當地經銷商
    • 全國經銷商
  • 線上
    • 電子商務平台
    • 製造商門戶

第13章 肺炎鏈球菌檢測市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肺炎鏈球菌檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國肺炎鏈球菌檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Hologic, Inc.
    • Bio-Rad Laboratories, Inc.
    • Seegene Inc.
    • Meridian Bioscience Inc.
Product Code: MRR-4103B31E098A

The Pneumococcal Testing Market is projected to grow by USD 3.67 billion at a CAGR of 9.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.80 billion
Estimated Year [2025] USD 1.97 billion
Forecast Year [2032] USD 3.67 billion
CAGR (%) 9.25%

A strategic primer highlighting how recent diagnostic advances, clinical imperatives, and surveillance needs are reshaping pneumococcal testing and laboratory priorities

Pneumococcal disease continues to present a complex clinical and public health challenge, and advances in testing are central to improving patient outcomes and informing prevention strategies. Diagnostics now operate at the intersection of molecular precision, rapid point-of-care delivery, and surveillance-driven public health interventions. As a result, laboratory directors, clinical microbiologists, and public health officials must weigh diagnostic accuracy, throughput, and timeliness against operational constraints and regulatory expectations.

Over recent years, diagnostic innovation has shifted the emphasis from purely culture-based identification to more nuanced molecular and serological approaches that enable earlier and more specific detection. This evolution aligns with expanding vaccination programs and heightened surveillance needs for serotype distribution and antibiotic resistance. Simultaneously, healthcare systems are recalibrating procurement and laboratory pathways to accommodate multiplexed platforms and integrated data reporting capabilities that better support clinical decision-making and epidemiological tracking.

In this context, stakeholders must balance near-term clinical utility with longer-term investments in infrastructure, workforce training, and information systems. The introduction of novel assays and analytic technologies demands careful validation and adoption strategies that preserve diagnostic quality while optimizing for real-world constraints. Ultimately, the choices made today in test selection, laboratory workflow, and surveillance design will define the next generation of pneumococcal control measures and their capacity to reduce morbidity and mortality.

How converging technological advances, integrated data systems, and shifting clinical pathways are fundamentally transforming pneumococcal testing and surveillance approaches

The landscape of pneumococcal testing is undergoing transformative shifts driven by technological maturation, changing clinical pathways, and evolving public health priorities. Molecular approaches that offer heightened sensitivity and the ability to detect multiple targets in a single assay are fostering a move away from sole reliance on traditional culture methods. At the same time, serological techniques have been refined for faster antibody and antigen detection, enabling more rapid assessments of immune status and vaccine effectiveness.

Testing is also becoming more integrated with digital health and laboratory information systems, which enhances data flow between clinical settings and public health authorities. This integration supports real-time surveillance of serotype prevalence and resistance patterns, and it enables more rapid public health responses. Furthermore, the diversification of point-of-care testing options is widening access in outpatient and community settings, thereby altering specimen collection pathways and diagnostic stewardship models.

Another significant shift is the emphasis on multiplexing and genomic methods that allow simultaneous pathogen identification and characterization. These approaches facilitate precise epidemiological tracking and inform vaccine policy decisions, while also placing new demands on laboratory bioinformatics and data governance. As a consequence, collaborations across diagnostic manufacturers, clinical laboratories, and public health institutions are accelerating, and strategic partnerships are increasingly central to deploying scalable, sustainable testing solutions.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resiliency, and platform selection across the pneumococcal diagnostics ecosystem

The introduction of tariffs in 2025 has had a multi-dimensional impact on the procurement, manufacturing, and distribution dynamics for pneumococcal testing supplies and equipment. Import duties and trade adjustments have influenced sourcing decisions for reagents, instruments, and consumables, prompting many stakeholders to reassess supplier portfolios and supply chain resiliency. In turn, diagnostic manufacturers and laboratory networks are recalibrating production and inventory strategies to maintain continuity of testing services.

Operationally, laboratories faced decisions about prioritizing existing platforms versus investing in alternative technologies that are less exposed to tariff-driven price volatility. Procurement teams responded by negotiating long-term supply agreements, expanding local distributor relationships, and in some cases accelerating investments in domestic production capacities. These shifts have also affected lead times and logistics planning, with organizations placing greater emphasis on dual-source strategies and buffer stock to mitigate disruptions.

Policy responses have been notable, with regulators and payers engaging to ensure access to essential diagnostics while balancing cost containment goals. Payers and hospital administrators intensified scrutiny of test utilization to preserve budgetary stability, which in turn influenced adoption timelines for higher-cost platforms. At the same time, tariff pressures catalyzed regionalization of supply chains, encouraging partnership models that prioritize supply security and compliance with local market requirements. Taken together, these dynamics underscore the importance of strategic procurement, flexible platform selection, and proactive supply chain governance in preserving diagnostic capacity under changing trade conditions.

In-depth segmentation analysis revealing how test modalities, enabling technologies, clinical applications, end-user settings, and distribution models collectively drive diagnostic adoption

Understanding segmentation is essential for aligning product development, market access, and laboratory adoption strategies. From a test-type perspective, the market spans culture based methods, molecular assays, and serological tools. Culture based testing remains relevant for antimicrobial susceptibility and confirmatory identification, and it is split across automated culture systems that improve throughput and conventional culture methods that remain indispensable in many diagnostic workflows. Molecular testing is characterized by the rise of digital PCR, multiplex PCR, and real time PCR modalities that deliver rapid, sensitive detection and enable simultaneous analysis of multiple targets. Serological approaches-encompassing enzyme-linked immunosorbent assays and rapid immunoassays-support immune status evaluation and vaccine response monitoring, with ELISA platforms commonly used for detailed serotype and antibody profiling while rapid immunoassays serve decentralized settings.

Technology segmentation further clarifies the competitive and clinical landscape. ELISA platforms are differentiated into indirect and sandwich formats that address diverse antigen-antibody dynamics, while immunochromatographic tests include dot blot and lateral flow assay formats suitable for rapid screening and point-of-care use. Next-generation sequencing platforms such as Illumina and Ion Torrent offer high-resolution serotype distribution and genomic surveillance capabilities, enabling deep insights into pathogen evolution. PCR assays remain a cornerstone technology with digital PCR offering absolute quantification, multiplex PCR enabling broadened target panels, and real time PCR providing a balance of speed and analytical performance.

Application-driven segmentation highlights how diagnostic utility varies across carrier screening, diagnosis, surveillance, and vaccine evaluation. Carrier screening practices differentiate nasopharyngeal and oropharyngeal sampling approaches, whereas diagnostic use spans clinical syndromes such as community-acquired pneumonia, meningitis, and otitis media. Surveillance activities focus on antibiotic resistance monitoring and serotype distribution to inform public health interventions, and vaccine evaluation relies on both preclinical trial data and postmarketing surveillance to measure real-world vaccine impact. End-user segmentation addresses the operational contexts in which tests are deployed, ranging from community health centers and outpatient clinics to large and small hospitals, local and state public health laboratories, and national and regional reference laboratories, each with distinct workflow, regulatory, and budget considerations. Finally, distribution channels vary across direct sales-whether via online direct portals or specialty sales teams-distributors operating at local and national scales, and online platforms that include ecommerce offerings and manufacturer portals, creating multiple go-to-market pathways and service models that suppliers must optimize to reach diverse buyers.

Comparative regional insights examining how policy frameworks, laboratory capacity, and supply chain strategies shape pneumococcal testing across global markets

Regional dynamics exert a major influence on diagnostic deployment, regulatory pathways, and investment priorities. In the Americas, clinical laboratories and public health agencies place emphasis on rapid, high-throughput testing to support both clinical management and broad surveillance needs. Health systems in this region tend to adopt multiplex and molecular platforms that integrate with electronic health records and public health reporting infrastructures, while payer systems drive consideration of cost-effectiveness and value-based testing pathways.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks, reimbursement models, and public health priorities vary significantly. In some territories, sophisticated reference laboratories and national surveillance programs leverage next-generation sequencing and genomic epidemiology to map serotype shifts, whereas in lower-resource settings there is greater reliance on point-of-care serological and immunochromatographic tests to expand access. Cross-border collaboration and capacity building remain central themes, and stakeholders increasingly prioritize harmonized data standards to enable comparable surveillance outputs across jurisdictions.

In the Asia-Pacific region, growth in diagnostic infrastructure and investments in local manufacturing are notable, with governments and private stakeholders emphasizing domestic capability for reagent production and instrument servicing. This region demonstrates rapid adoption of digital workflows and decentralized testing models, and it is an active arena for public-private collaborations aimed at scaling surveillance and vaccine evaluation programs. Across all regions, supply chain strategies and regulatory engagement are tailored to local market structures, and vendors must design flexible commercial models that account for these regional differences while ensuring quality and compliance.

Practical company-level intelligence showing how platform strategies, strategic partnerships, and operational support determine success in the pneumococcal diagnostics arena

Company-level dynamics center on platform diversification, strategic partnerships, and the alignment of commercial models with evolving laboratory needs. Diagnostic manufacturers are increasingly investing in product families that span central laboratory instruments, near-patient analyzers, and consumable ecosystems to secure recurring revenue and deepen customer relationships. This trend is accompanied by heightened focus on assays that enable multiplex detection, serotype differentiation, and integration with digital reporting tools that support surveillance and clinical decision support.

Partnerships between assay developers, instrument suppliers, and informatics providers are becoming more common as firms seek to offer end-to-end solutions that reduce implementation friction for laboratories. Similarly, contract manufacturing organizations and specialty reagent suppliers play an important role in ensuring supply continuity, particularly when geopolitical or trade policy changes introduce procurement uncertainty. Market competitors are also investing in regulatory pathways and clinical evidence generation to support broader indications, including use cases in outpatient settings and public health surveillance.

Laboratory networks and reference institutions exert influence through validation studies, protocol harmonization, and participation in external quality assessment programs, which in turn shape adoption patterns for new assays. Companies that demonstrate strong postmarket support, rapid technical service, and accessible training resources tend to achieve deeper penetration in decentralized settings. Overall, the most successful firms combine technological differentiation with pragmatic commercialization strategies that address the operational realities of diverse end users.

Concrete strategic actions for diagnostic and laboratory leaders to enhance interoperability, supply chain resilience, evidence generation, and tailored commercialization approaches

Industry leaders should prioritize a set of actionable measures to solidify market position and support public health objectives. First, investing in platform interoperability and data integration capabilities will improve adoption, as laboratories increasingly require seamless connectivity between instruments, laboratory information systems, and public health databases. By addressing integration barriers, companies can accelerate time-to-value for customers and strengthen long-term relationships.

Second, enhancing supply chain resilience through diversified sourcing, regional manufacturing partnerships, and scalable inventory strategies will reduce exposure to trade-related disruptions and tariff volatility. Strategic procurement arrangements and transparent communication with customers about lead times and contingency plans will bolster trust and operational continuity. Third, targeted evidence generation that validates performance across clinical syndromes, specimen types, and demographic populations will support broader clinical acceptance and regulatory flexibility. Robust postmarket surveillance and real-world performance data will also inform iterative product improvements.

Fourth, tailoring go-to-market approaches to end-user needs-differentiating offerings for community clinics, large hospital systems, public health labs, and reference laboratories-will improve market penetration. This includes offering modular training, remote support, and flexible commercial terms that reflect the purchasing realities of each segment. Finally, companies should engage proactively with public health stakeholders and payers to align diagnostic value propositions with policy priorities and reimbursement frameworks. These combined actions will help leaders navigate uncertainty while delivering durable clinical and public health value.

Comprehensive blended research methodology combining stakeholder interviews, literature synthesis, and cross-segmentation analysis to produce pragmatic diagnostic and policy insights

The research underpinning these insights combined a multi-modal approach to ensure comprehensiveness and practical relevance. Primary research included structured interviews and qualitative consultations with laboratory directors, clinical microbiologists, procurement leads, and public health officials to capture on-the-ground operational perspectives and decision criteria. These stakeholder engagements provided detailed context on platform selection, validation requirements, and supply chain sensitivities, and they informed the interpretation of emerging trends in diagnostics and surveillance.

Secondary research synthesized publicly available regulatory guidance, technical white papers, and peer-reviewed literature on pneumococcal diagnostics, serotype epidemiology, and testing methodologies. Emphasis was placed on peer-reviewed validation studies and official public health communications to ensure that technological assessments were grounded in rigorous evidence. Where appropriate, company disclosures and product technical specifications were reviewed to map feature sets and integration capabilities across competing platforms.

Analytical methods included cross-segmentation mapping to identify where clinical needs intersect with technological capabilities, and scenario analysis to explore how supply chain or policy shifts could alter adoption pathways. Quality assurance measures involved validation of qualitative findings with multiple independent sources and iterative review by clinical experts to ensure that interpretations reflected practical realities. This blended methodology supports robust, actionable insights that can guide procurement decisions, platform investments, and policy engagement.

Final synthesis emphasizing the interplay between technological innovation, supply chain robustness, and collaborative public health strategies to reduce pneumococcal disease burden

In closing, the pneumococcal testing environment is at an inflection point where technological capability, supply chain realities, and public health priorities converge. Molecular and sequencing technologies are unlocking new diagnostic and surveillance possibilities, while serological assays and point-of-care formats continue to expand access in decentralized settings. These complementary modalities create a richer toolkit for clinicians and public health authorities but also demand greater attention to interoperability, validation, and quality assurance.

The cumulative effect of recent policy changes and trade dynamics has reinforced the need for resilient procurement strategies and adaptable commercial models. At the same time, regional differences in regulatory and laboratory capacity require suppliers to offer flexible deployment options that account for local constraints and priorities. Companies and laboratory networks that proactively address integration, evidence generation, and supply security will be best positioned to support both immediate clinical needs and longer-term public health objectives.

Ultimately, successful navigation of this landscape depends on close collaboration across manufacturers, laboratories, and public health institutions, guided by transparent data sharing and pragmatic implementation pathways. By aligning technological innovation with operational realities and stakeholder needs, the diagnostics community can contribute meaningfully to reducing the burden of pneumococcal disease and strengthening surveillance systems for the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiplex molecular assays for rapid differentiation of pneumococcal serotypes and co-circulating respiratory pathogens
  • 5.2. Expansion of point-of-care polymerase chain reaction testing for pneumococcal detection in underserved and resource-limited settings
  • 5.3. Adoption of next-generation sequencing for high-resolution surveillance of pneumococcal strain diversity and antibiotic resistance profiles
  • 5.4. Development of automated sample-to-answer platforms to accelerate pneumococcal testing workflows in hospital and clinical laboratory settings
  • 5.5. Implementation of cloud-based data analytics and digital reporting tools for real-time monitoring of pneumococcal infection outbreaks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Testing Market, by Type Of Test

  • 8.1. Culture Based
    • 8.1.1. Automated Culture
    • 8.1.2. Conventional Culture
  • 8.2. Molecular
    • 8.2.1. Digital PCR
    • 8.2.2. Multiplex PCR
    • 8.2.3. Real Time PCR
  • 8.3. Serological
    • 8.3.1. Elisa
    • 8.3.2. Rapid Immunoassay

9. Pneumococcal Testing Market, by Technology

  • 9.1. Elisa
    • 9.1.1. Indirect Elisa
    • 9.1.2. Sandwich Elisa
  • 9.2. Immunochromatographic Test
    • 9.2.1. Dot Blot
    • 9.2.2. Lateral Flow Assay
  • 9.3. Next-Generation Sequencing
    • 9.3.1. Illumina Platform
    • 9.3.2. Ion Torrent
  • 9.4. Pcr Assay
    • 9.4.1. Digital PCR
    • 9.4.2. Multiplex PCR
    • 9.4.3. Real Time PCR

10. Pneumococcal Testing Market, by Application

  • 10.1. Carrier Screening
    • 10.1.1. Nasopharyngeal Screening
    • 10.1.2. Oropharyngeal Screening
  • 10.2. Diagnosis
    • 10.2.1. Community Acquired Pneumonia
    • 10.2.2. Meningitis
    • 10.2.3. Otitis Media
  • 10.3. Surveillance
    • 10.3.1. Antibiotic Resistance Monitoring
    • 10.3.2. Serotype Distribution
  • 10.4. Vaccine Evaluation
    • 10.4.1. PostMarketing Surveillance
    • 10.4.2. PreClinical Trials

11. Pneumococcal Testing Market, by End User

  • 11.1. Clinics
    • 11.1.1. Community Health Centers
    • 11.1.2. Outpatient Clinics
  • 11.2. Hospitals
    • 11.2.1. Large Hospitals
    • 11.2.2. Small Hospitals
  • 11.3. Public Health Labs
    • 11.3.1. Local Public Health Labs
    • 11.3.2. State Public Health Labs
  • 11.4. Reference Labs
    • 11.4.1. National Reference Labs
    • 11.4.2. Regional Reference Labs

12. Pneumococcal Testing Market, by Distribution Channel

  • 12.1. Direct Sales
    • 12.1.1. Online Direct
    • 12.1.2. Specialty Sales Team
  • 12.2. Distributors
    • 12.2.1. Local Distributors
    • 12.2.2. National Distributors
  • 12.3. Online
    • 12.3.1. Ecommerce Platforms
    • 12.3.2. Manufacturer Portals

13. Pneumococcal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pneumococcal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pneumococcal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Becton, Dickinson and Company
    • 16.3.4. bioMerieux SA
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. QIAGEN N.V.
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. Seegene Inc.
    • 16.3.10. Meridian Bioscience Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PNEUMOCOCCAL TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2